Press Releases

Press Releases

Date Title  
Dec 05, 2019 Omeros Announces Pricing of Upsized Public Offering of Common Stock
SEATTLE --(BUSINESS WIRE)--Dec. 5, 2019-- Omeros Corporation (Nasdaq: OMER) (“Omeros”), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting
Dec 04, 2019 Omeros Announces Proposed Public Offering of Common Stock
SEATTLE --(BUSINESS WIRE)--Dec. 4, 2019-- Omeros Corporation (Nasdaq: OMER) (“Omeros”), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting
Dec 04, 2019 Omeros Reports Positive Data Across Primary and Secondary Endpoints in Pivotal Trial of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Patients Treated with Narsoplimab
– 56 Percent of All Narsoplimab-Treated Patients Were Complete Responders by Primary Endpoint, Achieving Full Set of Response Criteria Agreed by FDA ; 68 Percent Primary-Endpoint Complete Response Rate for Those Who Received Protocol-Specified Treatment of At Least 4 Weeks of Dosing – – 100-Day
Nov 20, 2019 Omeros’ New GPR174 Immuno-oncology Data Presented at the American Association for Cancer Research Conference In Boston Now Available Online
SEATTLE --(BUSINESS WIRE)--Nov. 20, 2019-- Omeros Corporation (Nasdaq: OMER) presented new GPR174 immuno-oncology data yesterday at the American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy in Boston, Massachusetts .
Nov 19, 2019 Omeros Presents New GPR174 Immuno-oncology Data Today at the American Association for Cancer Research Conference in Boston
-- GPR174 Deficiency Improves Outcomes in Animal Tumor Models -- SEATTLE --(BUSINESS WIRE)--Nov. 19, 2019-- Omeros Corporation (Nasdaq: OMER) today announced new findings on GPR174, its novel cancer immunotherapy target, demonstrating that GPR174-deficiency enhances anti-tumor immune responses in
Nov 12, 2019 Omeros Corporation Reports Third Quarter 2019 Financial Results
Conference Call Today at 4:30 p.m. ET SEATTLE --(BUSINESS WIRE)--Nov. 12, 2019-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan
Nov 08, 2019 Omeros to Present GPR174 Data at Upcoming American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy
SEATTLE --(BUSINESS WIRE)--Nov. 8, 2019-- Omeros Corporation (Nasdaq: OMER) today announced an upcoming presentation entitled “Phosphatidylserine suppresses T cells through GPR174, and co-inhibition of adenosine receptors and GPR174 synergistically enhances T-cell responses” at the American
Nov 07, 2019 Omeros Scientists Win 2019 Prix Galien Research Award
--Prestigious Prize Conferred for GPCR Program Discoveries-- SEATTLE --(BUSINESS WIRE)--Nov. 7, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that three of its scientists––Alexander Gragerov, Ph.D., associate vice president of research, George A.
Nov 06, 2019 Omeros Corporation to Announce Third Quarter 2019 Financial Results on November 12, 2019
SEATTLE --(BUSINESS WIRE)--Nov. 6, 2019-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its third quarter 2019 financial results for the period ended September 30, 2019 , on Tuesday, November 12, 2019 , after the market closes.
Nov 04, 2019 Omeros Corporation Announces Publication of Study Results on the Impact of OMIDRIA on Opioid Use and Pain
-- Study Demonstrates Opioid-Sparing Requirement of OMIDRIA for CMS Packaging Exclusion -- SEATTLE --(BUSINESS WIRE)--Nov. 4, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that results of a prospective, controlled study showing that its FDA -approved ophthalmic drug OMIDRIA ®
Oct 29, 2019 Omeros’ Narsoplimab Receives Positive Opinion from European Medicines Agency for Pediatric Investigation Plan Required for MAA Submission
– Includes Deferral for PIP Completion Until After Approval of Marketing Authorization Application – SEATTLE --(BUSINESS WIRE)--Oct. 29, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that the Pediatric Committee (PDCO) of the European Medicines Agency (EMA) has issued a positive opinion
Oct 28, 2019 Omeros Corporation Initiates BLA Submission for Narsoplimab for the Treatment of HSCT-TMA
– Rolling Submission of the Remaining BLA Sections Continues On Track for Scheduled Completion 1H 2020 – SEATTLE --(BUSINESS WIRE)--Oct. 28, 2019-- Omeros Corporation (Nasdaq: OMER) has submitted the first sections of the rolling submission of its Biologics License Application (BLA) to the U.S.
Oct 01, 2019 Product-Specific J-Code for Omeros’ OMIDRIA® is Now in Effect
  SEATTLE --(BUSINESS WIRE)--Oct. 1, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that the product-specific J-code for OMIDRIA ® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% is now effective. OMIDRIA is Omeros’ commercial drug marketed for use during cataract surgery to
Sep 25, 2019 Omeros Announces Publication of Study Showing that Inhibition of MASP-2, the Key Enzyme of the Complement System’s Lectin Pathway, Protects Against Renal Injury Caused by Proteinuria
  SEATTLE --(BUSINESS WIRE)--Sep. 25, 2019-- Omeros Corporation (Nasdaq: OMER) today announced publication of study results showing that inhibition of mannan-binding lectin-associated serine protease-2 (MASP-2) protects against renal injury caused by proteinuria ( i.e.
Sep 16, 2019 Omeros Corporation Announces Positive Results from Phase 1 Study of its Lead PDE7 Inhibitor in Development for Addiction
-- Phase 1 study results show excellent safety and PK profile consistent with once-daily dosing -- SEATTLE --(BUSINESS WIRE)--Sep. 16, 2019-- Omeros Corporation (Nasdaq: OMER) today announced positive results from its Phase 1 study with the lead compound in its OMS527 program.
Sep 11, 2019 FDA Confirms Omeros’ Schedule for Rolling Review of the Company’s BLA for Narsoplimab in the Treatment of HSCT-TMA
– Omeros Remains On Track to Initiate the Submission Next Quarter – SEATTLE --(BUSINESS WIRE)--Sep. 11, 2019-- Omeros Corporation (Nasdaq: OMER) announced that the United States Food and Drug Administration ( FDA ) agreed with the company’s proposed schedule for the rolling review of the Biologics
Sep 10, 2019 Omeros Discovers New Cancer-Immunity Pathways Controlled by GPR174
-- The Company’s GPR174 Inhibitors Enhance Anti-Tumor Activities of Adenosine Pathway Inhibitors by up to 25-Fold -- SEATTLE --(BUSINESS WIRE)--Sep. 10, 2019-- Omeros Corporation (Nasdaq: OMER) today announced a new approach to cancer immunotherapy that targets inhibition of GPR174, a member of the
Sep 06, 2019 Omeros to Present at the H.C. Wainwright 21st Annual Global Investment Conference
SEATTLE --(BUSINESS WIRE)--Sep. 6, 2019-- Omeros Corporation (Nasdaq: OMER), today announced that Gregory A. Demopulos , M.D., chairman and chief executive officer, will present at the H.C. Wainwright 21 st Annual Global Investment Conference in New York next week.
Aug 09, 2019 Omeros to Present at the 2019 Wedbush PacGrow Healthcare Conference
SEATTLE --(BUSINESS WIRE)--Aug. 9, 2019-- Omeros Corporation (Nasdaq: OMER), today announced that Gregory A. Demopulos , M.D., chairman and chief executive officer, will present at the 2019 Wedbush PacGrow Healthcare Conference in New York next week. The presentation is scheduled for Wednesday,
Aug 08, 2019 Omeros Corporation Reports Second Quarter 2019 Financial Results
– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--Aug. 8, 2019-- Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan
Aug 05, 2019 Omeros Corporation to Announce Second Quarter 2019 Financial Results on August 8, 2019
SEATTLE --(BUSINESS WIRE)--Aug. 5, 2019-- Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its second quarter 2019 financial results for the period ended June 30, 2019 , on Thursday, August 8, 2019 , after the market closes.
Jul 31, 2019 Omeros and Lonza Enter Long-Term Manufacturing Agreement for Commercial Supply of Narsoplimab
SEATTLE & BASEL, Switzerland --(BUSINESS WIRE)--Jul. 31, 2019-- Omeros Corporation (Nasdaq: OMER) and Lonza (SWX: LONN) today announced a long-term manufacturing agreement for commercial production of narsoplimab, Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated
Jul 24, 2019 Omeros’ OMIDRIA® Receives Product-Specific J-Code from CMS
-- Effective October 1, 2019 , New Code Expected to Expand Reimbursement -- SEATTLE --(BUSINESS WIRE)--Jul. 24, 2019-- Omeros Corporation today announced that the Centers for Medicare and Medicaid Services (CMS) confirmed its preliminary decision to assign a permanent product-specific Healthcare
Jul 11, 2019 Omeros Announces Agreement with FDA on Primary Endpoint for Narsoplimab BLA in Stem Cell Transplant-Associated TMA
-- All Criteria for the Response-Based Endpoint Now Finalized -- SEATTLE --(BUSINESS WIRE)--Jul. 11, 2019-- Omeros Corporation today announced agreement with the U.S. Food and Drug Administration ( FDA ) on the response-based primary endpoint for its pivotal trial to support the biologics license
Jun 05, 2019 Omeros Corporation Announces Assignment of Rapporteurs for European Marketing Authorization Application for Narsoplimab for Treatment of HSCT-TMA
– Preparations Continue for Submission of BLA in the U.S. and MAA in Europe – SEATTLE --(BUSINESS WIRE)--Jun. 5, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that the European Medicines Agency (EMA) has appointed rapporteurs for the company’s marketing authorization application (MAA)
May 15, 2019 Omeros to Present at the UBS Global Healthcare Conference
SEATTLE --(BUSINESS WIRE)--May 15, 2019-- Omeros Corporation (NASDAQ: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the UBS Global Healthcare Conference in New York next week. The presentation is scheduled for Wednesday, May 22, 2019 at
May 09, 2019 Omeros Corporation Reports First Quarter 2019 Financial Results
– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--May 9, 2019-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan
May 07, 2019 Clinical Study Showing Reduced Incidence of Cystoid Macular Edema with OMIDRIA® Presented at American Society of Cataract and Refractive Surgery Annual Meeting
- Cataract surgery performed using OMIDRIA had lower rates of CME than cataract surgery using postoperative steroids- SEATTLE --(BUSINESS WIRE)--May 7, 2019-- Omeros Corporation  (Nasdaq: OMER) today announced the results of a real-world clinical study showing that its FDA -approved ophthalmic drug
May 06, 2019 Omeros Corporation to Announce First Quarter 2019 Financial Results on May 9, 2019
SEATTLE --(BUSINESS WIRE)--May 6, 2019-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter 2019 financial results for the period ended March 31, 2019 , on Thursday, May 9, 2019 , after the market closes. Omeros management will host a conference call
May 01, 2019 Omeros Corporation Announces Presentation of OMIDRIA® Real-World Data at Upcoming American Society of Cataract and Refractive Surgery Annual Meeting
SEATTLE --(BUSINESS WIRE)--May 1, 2019-- Omeros Corporation  (Nasdaq: OMER) today announced that the results of an investigator-sponsored real-world study of its FDA -approved ophthalmic drug OMIDRIA ® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% will be presented at the American
Apr 03, 2019 Omeros Corporation Announces EBMT Case Report of Resolution of Gastrointestinal Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Following Narsoplimab Treatment
-- Growing Identification of HSCT-TMA a Focus of Recent Annual Meeting of the European Society for Blood and Marrow Transplantation -- SEATTLE --(BUSINESS WIRE)--Apr. 3, 2019-- Omeros Corporation  (Nasdaq: OMER) today announced the recent presentation of a case report describing resolution of
Mar 19, 2019 Omeros Corporation Announces Upcoming Educational Event at the Annual Meeting of the European Society of Blood and Marrow Transplantation
--Session Will Focus on Diagnosis of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy-- SEATTLE --(BUSINESS WIRE)--Mar. 19, 2019-- Omeros Corporation  (Nasdaq: OMER) today announced an upcoming educational event at the 2019 Annual Meeting of the European Society of Blood and
Mar 01, 2019 Omeros Corporation Reports Fourth Quarter and Year-End 2018 Financial Results
– Conference Call Today at 8:30 a.m. ET – SEATTLE --(BUSINESS WIRE)--Mar. 1, 2019-- Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan
Feb 26, 2019 Omeros Corporation to Announce Fourth Quarter and Year-End 2018 Financial Results on March 1, 2019
SEATTLE --(BUSINESS WIRE)--Feb. 26, 2019-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end 2018 financial results for the period ended December 31, 2018 , on Friday, March 1, 2019 , before the market opens.
Feb 20, 2019 Omeros Corporation Announces USAN and INN Selection of Nonproprietary Name for OMS721
SEATTLE --(BUSINESS WIRE)--Feb. 20, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that, as the company prepares for planned commercialization of OMS721, the United States Adopted Names (USAN) Council , in consultation with the World Health Organization’s International Nonproprietary
Feb 14, 2019 Omeros Corporation Streamlines Path to Biologics License Application for OMS721 in HSCT-TMA Following Meeting with FDA
Patient Data from Existing Single-Arm Study Will Form the Basis for BLA; No Historical Control Required SEATTLE --(BUSINESS WIRE)--Feb. 14, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that, based on a recent meeting with the U.S. Food and Drug Administration ( FDA ), the company has
Feb 12, 2019 Omeros Corporation Appoints Thomas F. Bumol, Ph.D., to Board of Directors
-- Former Lilly Biotechnology and Immunology Senior Vice President Drawn by Omeros’ Complement Franchise and Novel-Product Pipeline -- SEATTLE --(BUSINESS WIRE)--Feb. 12, 2019-- Omeros Corporation (NASDAQ: OMER) today announced the appointment of Thomas F. Bumol , Ph.D., to its Board of Directors.
Jan 17, 2019 Omeros Finalizes with FDA Clinical Plan for OMS721 Approval in IgA Nephropathy
--Additional Positive Data Reported from Second Cohort in Phase 2 Trial-- SEATTLE --(BUSINESS WIRE)--Jan. 17, 2019-- Omeros Corporation (Nasdaq: OMER) today announced that it has finalized its clinical plan for OMS721 submission and approval in immunoglobulin A nephropathy (IgAN) following a recent
Jan 14, 2019 Omeros Corporation Announces Record High Quarterly Revenue Results for the Fourth Quarter 2018
– Broadening OMIDRIA Coverage from Payers and Increasing Funding for OMS721 Commercial Preparations – SEATTLE --(BUSINESS WIRE)--Jan. 14, 2019-- Omeros Corporation (Nasdaq: OMER), today announced unaudited preliminary revenue results for the fourth quarter ended December 31, 2018 .